Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Japanese RA patients on MTX
NCT01469013Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Nov 2011; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01469013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01469013.